Australia's most trusted
source of pharma news
Thursday, 27 June 2024
Posted 20 May 2024 AM
Astellas' top-earning drug Xtandi is officially under threat in Australia after Indian generics manufacturer Cipla registered the first copycat of the prostate cancer pill last week.
Xtandi made $149 million in pre-rebate PBS benefits in the year to March 2024, a 23 per cent year-on-year increase. In the first quarter of this year alone, it earned the company $39.5 million.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.